A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder Clinical Trial

Official title:

A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00606177
• Other study ID #: 031-06-004
• Status: Completed
• Phase: Phase 3
• First received: January 19, 2008
• Last updated: January 16, 2014
• Start date: January 2008
• Est. completion date: November 2010

Study information

• Verified date: January 2014
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

To investigate the safety and efficacy of long-term administration of aripiprazole by performing extended administration of the treatment administered in the preceding multicenter, double-blind, placebo-controlled, parallel group-comparison trial of aripiprazole in patients with bipolar disorder experiencing a manic or mixed episode (Study 031-06-003, hereafter "Study 003") in a double-blind manner to those patients who complete Study 003 and demonstrate drug efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Trial subjects will be men and women of age 18 or above and below the age of 65 who will not be turning 65 during the trial.

• Subjects have the ability to understand and to provide informed consent to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial.

• Subjects who meet DSM-IV-TR criteria for manic or mixed episodes and have been diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"

• Subjects who were enrolled in and have completed Study 003 and who meet the following criteria for demonstration of drug efficacy

• Subjects demonstrating drug efficacy:

• Those subjects who completed Study 003 whose score for CGI-BP Change From Preceding Phase (mania) at the time of evaluation on Day 21 of Study 003 (completion) was between 1 (Very much improved) and 3 (Minimally improved)

Exclusion Criteria:

• Subjects presenting with a clinical picture and/or history that is consistent with a DSM-IV-TR diagnosis of:

• Delirium, dementia, amnestic disorder, or other cognitive disorders

• Schizophrenia or other psychotic disorder

• Personality disorder

• Subjects with psychotic symptoms that are clearly due to another general medical condition or direct physiological effects of a substance

• Subjects who represent a significant risk of committing suicide

• Subjects known to have a complication of allergy to aripiprazole or other quinolinone-skeleton compounds

• Subjects with a complication of neuroleptic malignant syndrome

• Subjects in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition

• Subjects with a complication of paralytic ileus

• Subjects with a complication of organic brain disorder or convulsive disorder, such as epilepsy

• Subjects with a complication of diabetes

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bipolar Disorder
• Bipolar I Disorder

Intervention

Drug:
• Aripiprazole
oral, 24mg(4 tablets)/day
• placebo
oral, 0mg(4tablets)/day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Countries where clinical trial is conducted

China,  Japan,  Korea, Republic of,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Young Mania Rating Scale (YMRS)	Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group.; YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior.; YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome).	Baseline (Day 1 of preceding study) , Day 154 or at discontinuation	No
Secondary	Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)	Using LOCF datasets, descriptive statistics of actual values for change of CGI-BP severity of illness score (mania) from baseline (Day 1 of preceding study) to endpoint (Day 154) were calculated for each treatment group.; CGI-BP severity of illness is a scale for overall evaluation of the severity of bipolar disorder; it comprises 3 components—mania, depression, and overall bipolar illness.; CGI-BP severity of illness score (mania) ranges form 1 (normal, not ill) to 7 (very severely ill).	Baseline (Day 1 of preceding study), Day 154 or at discontinuation	No